Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

CompletedOBSERVATIONAL
Enrollment

99

Participants

Timeline

Start Date

February 18, 2016

Primary Completion Date

March 31, 2016

Study Completion Date

May 19, 2016

Conditions
Age-related Macular Degeneration (AMD)Central Retinal Vein Occlusion (CRVO)Diabetic Macular Edema (DME)
Interventions
DRUG

Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY